#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 13, 2011

#### Lifevantage Corporation

(Exact Name of Registrant as Specified in Charter)

**Colorado** (State or Other Jurisdiction of Incorporation) **000-30489** (Commission File Number) **90-0224471** (IRS Employer Identification No.)

**11545 W. Bernardo Court, Suite 301, San Diego, California** (Address of Principal Executive Offices) **92127** (Zip Code)

Registrant's Telephone Number, Including Area Code: (858) 312-8000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 7.01. Regulation FD Disclosure.

Douglas C. Robinson, President and Chief Executive Officer of Lifevantage Corporation (the "Company"), and Carrie McQueen, the Company's Chief Financial Officer, intend to present the information attached hereto as Exhibit 99.1, in whole or in part, in one or more investor relations discussions. A copy of the investor presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the foregoing information, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall such information, including Exhibit 99.1, be deemed incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.

The information contained in the slides is summary information that is intended to be considered in the context of Lifevantage Corporation's filings with the Securities and Exchange Commission (the "SEC") and other public announcements that Lifevantage makes, by press release or otherwise, from time to time. Lifevantage undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

#### Item 9.01. Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Investor Presentation dated June 13, 2011

-2-

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: June 13, 2011

#### Lifevantage Corporation

By: /s/ Carrie E. McQueen Carrie E. McQueen

Chief Financial Officer, Secretary & Treasurer

-3-

### LifeVantage Corporation

Investor Presentation Accredited Members Summer 2011 Investment Research Conference June 13, 2011



### **Forward Looking Statements**

This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, the potential failure or unintended negative consequences of the implementation of the Company's network marketing sales channel; the Company's ability to retain independent distributors or to attract new independent distributors on an ongoing basis; the potential for third party and governmental actions involving the Company's network marketing sales channel; the potential for product liability claims against the Company; the risk that government regulators and regulations could adversely affect the Company's business; future laws or regulations may hinder or prohibit the production or sale of the Company's existing product and any future products; unfavorable publicity could materially hurt the Company's business; and the Company's ability to protect its intellectual property rights and the value of its product. These and other risk factors are discussed in greater detail in the Company's Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption "Risk Factors", and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this presentation. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

Lifevantage.

# **Management Presenters**



3

#### **Douglas C. Robinson**

President & Chief Executive Officer

#### **Carrie McQueen**

Chief Financial Officer

#### **Brooks Hybertson**

Scientific Advisory Board

# **Company Snapshot**



4

Ticker (OTCBB)	LFVN
Stock Price (as of 6/10/11)	\$1.52
Shares Outstanding (as of 6/8/11)	85 Million
Equity Market Cap (as of 6/10/11)	\$120 Million
FY11 9 Mo. Revenue	\$23.9 Million (241% y/y increase)
FY11 9 Mo. Operating Income	\$1.7 Million
FY11 9 Mo. Cash Flow	\$2.4 Million
Fiscal Year End	June 30 <sup>th</sup>
Year Founded	2003
Headquarters	San Diego

# Who We Are



LifeVantage is a nutraceutical production and distribution company that offers unique, science-based products in the rapidly growing sales channel for dietary supplements

- Flagship product, Protandim<sup>®</sup>, backed by patents, considerable research, and peer-reviewed studies
- LifeVantage TrueScience<sup>®</sup>, a scientifically based skin cream that reduces the signs of aging
- Products address multi-billion dollar dietary supplement & anti-aging skincare markets
- Products marketed & sold through the network marketing industry
  - · Fastest growing sales channel for dietary supplements
  - · Has an appealing value proposition during times of challenging economic conditions



## **Investment Highlights**



- Products Backed by Science
  - · Supported by multiple independent studies conducted by universities
- Significant Market Opportunity
  - · Increased consumer awareness about diet and health
  - Large and expanding nutraceutical market
- International Presence
  - Products sold in the U.S., Japan and Mexico, through a network of independent distributors and preferred and direct customers
- Experienced Management Team & Industry Leading Board of Directors
  - Company led by an experienced team of executives and distributors with a proven track record in network marketing
- Rapidly Growing Revenue Stream
  - First 9 Month FY11 net revenue of approximately \$23.9 million, 241% increase compared to prior year period
  - FY10 net revenue of approximately \$11.5 million (year ended June 30, 2010)
- Generated Operating Income in Q3 FY11

# Strong Management



Name	Title	Select Experience
Douglas C. Robinson	President & CEO	WorkWell Systems; UnitedHealth Group; Deloitte Consulting; PricewaterhouseCoopers
Carrie E. McQueen	CFO	Qthink, Inc.; Genelux Corporation; ADVENTRX Pharmaceuticals, Inc.; Singlefin, Inc.; V-Enable, Inc., Websense, Inc.
Joe M. McCord, Ph.D.	Chief Scientific Officer	Professor of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, the University of Colorado
David W. Brown	President of Network Marketing Operations	Nutrition Business Advisors; Metabolife International; Natural Balance, Inc.
		7

# Large, Growing Market



#### **Supplement Market**

- In the US, supplement industry generated \$26.9 billion in sales in 2009 and an estimated \$28.7 billion in 2010<sup>(1)</sup>
- Projected to grow at an average annual rate of approximately 5.3% through 2015<sup>(1)</sup>



<sup>(1) 2010,</sup> Nutrition Business Journal

- (2) 2005, Nutrition Business Journal
  (3) 2007, Business Communications Co.; 2007, The Freedonia Group
- (4) 2006, Euromonitor International
- (5) 2007, Sporting Goods Manufacturers Association

#### **The Anti-Aging Market**

- Over \$100 billion per year is spent fighting the aging process:
  - Anti-Aging supplements (About \$5 Billion)<sup>(2)</sup>
  - Anti-Aging services and related products (about \$50 billion) with demand expected to rise<sup>(3)</sup>
  - Other cosmetic products such as make-up (about \$50 billion)<sup>(4)</sup>
  - Exercise equipment (about \$5 billion) <sup>(5)</sup>



# Our Challenge...



"... Aging is really not about preventing disease; getting rid of heart disease and cancer gains us less than a decade of life. Rather we need to slow the rate of aging to avoid the frailty that would make longevity less desirable."

Dr. Mehmet Oz

Vice-Chair and Professor of Surgery, Columbia University; Times Best-Selling Author; Health Expert "Oprah Winfrey Show"

#### It's All About Prevention!



# **Oxidative Stress**



10

- Cellular & tissue damage caused by chemically reactive oxygen radicals (ROS) formed as a natural consequence of cellular metabolism
- Widely believed to be a key factor in aging process by triggering premature cell death
- As body ages, the body's defenses against oxidative stress and free radicals decrease
- Linked as a causative factor in over 100 diseases
- Lowering oxidative stress levels known to improve overall health & wellness
  - Enzymes present in the body serve to inactivate ROS
    - Two such enzymes are SOD & CAT (levels of which decrease with age)
- Nutritional benefits of food containing "direct" antioxidants widely known ... however, significant limitations have been found
  - Scientists estimate that an individual would need to consume the following levels of direct antioxidants to neutralize the free radicals produced in the body in a single day



# **Our Scientific Breakthrough**



# LifeVantage has a scientifically demonstrated breakthrough to help combat oxidative stress



### Protandim<sup>®</sup>, the Nfr2 Synergizer™ Dietary Supplement



#### > What is Protandim<sup>®</sup>?

- Unique, patented blend of phytonutrients
- Protandim<sup>®</sup> activates a signaling molecule called Nrf2, which upregulates genes encoding antioxidant enzymes, anti-inflammatory genes, and antifibrosis genes (the "survival genes")
- Combats oxidative stress by increasing the body's own production of powerful, natural antioxidant enzymes at the genetic level
- Safe and healthy dietary supplement (free of substances banned by such organizations as the International Olympic Committee, the NCAA, and the NFL
- Protected by Three U.S. Patents
  - $\checkmark$  Two composition of matter patents granted in 2007 & 2008
  - ✓ One methods and use patent granted in 2009

### Protandim<sup>®</sup> - Academic Confirmation

#### The Protandim<sup>®</sup> breakthrough study has spawned many additional independent studies using Protandim<sup>®</sup>

#### • Universities and institutions conducting research include:

- ✓ University of Colorado
- ✓ Harvard University
- ✓ Children's Hospital, Denver
- ✓ VU University, Amsterdam, the Netherlands
- ✓ Northwestern University
- ✓ University of Michigan
- ✓ Louisiana State University

🕒 Lifevantage.

### Protandim<sup>®</sup> - Academic Confirmation

#### Topics under investigation or in planning stages deal with the alleviation of oxidative stress under the following conditions:

- ✓ Altitude sickness
- ✓ Skin cancer
- ✓ Smoking cessation
- ✓ Renal failure
- ✓ Osteoarthritis
- ✓ HIV/AIDS-associated lipodystrophy
- ✓ Pulmonary hypertension
- ✓ Periodontal disease

- ✓ Heart disease
- ✓ Coronary artery bypass graft failure
- 🗸 Asthma
- ✓ Duchenne muscular dystrophy
- ✓ Metabolic syndrome
- ✓ Non-alcoholic fatty liver disease
- ✓ Multiple Sclerosis
- ✓ Alcoholism

Scientific evidence of Protandim<sup>®</sup>'s effectiveness against disease is rapidly growing.

14

🗖 Lifevantage.

### TrueScience<sup>®</sup> Anti-Aging Skin Cream

- Scientifically-based, unique skin care line launched in June 2009
   Formulated to protect the skin from a variety of factors that contribute to aging and the
- Robust market potential for anti-aging skincare products

symptoms of unhealthy skin

- Contains the ingredients of Protandim<sup>®</sup>, found to prevent cell damage internally
  - Key complementary product for Protandim<sup>®</sup> dietary supplement
- Safe, natural, & supported by dermatologists





### Distribution Strategy – Network Marketing



Sales of nutritional and personal care products have historically done very well in this channel

 Examples: Amway, Avon, and Herbalife

 Model allows for a comprehensive and individualized approach to the introduction to products and associated benefits

 Sales of nutritional and personal care products are strengthened by ongoing personal contact between consumers and distributors

 In 2009, more than \$15 billion in U.S. nutrition industry sales were generated from non-retail channels, including the Internet, network marketers, healthcare practitioners, direct response TV, direct response radio, and mail-order catalogs/direct mail<sup>(1)</sup>

(1) 2010, Nutrition Business Journal

# **Distributor Growth**



- Distributor growth a key driver of expanding product awareness and future revenue growth
- > Distributors attracted to our effective, scientifically demonstrated products
- > Held inaugural Global Network Marketing Convention in April
  - Over 2,000 distributors and guests in attendance
  - Recognized top distributors (including first Master Pro 10 Distributor, who achieved monthly organizational sales volume of \$1 million)
  - · Educates, motivates, and energizes distributors
- Geographic diversity: currently sell our products in the US, Mexico, and Japan
  - Began accepting applications for potential distributors in Australia in May 2011
  - Exploring additional markets


# **Recent Financial Highlights**



- Q3 FY11 net revenue increased 270% on a year-overyear basis and 35% on a sequential basis
- Selling & Marketing and R & D costs increased, reflecting strategic investments to grow our business
- Generated operating income of \$792,000
  - Third consecutive quarter of positive operating income
- First 9 Months FY11 Cash Flow from Operations improved to \$2.4 million
- Improved cash, cash equivalents and investments available for sale to \$4.4 million
- Raised annual revenue and operating income guidance

# Strong Revenue Growth





\* Forecasted revenue for Q4 assumes midpoint of annual FY11 revenue guidance 19

### **Improving Balance Sheet**



- Committed to improving balance sheet and overall financial health of LifeVantage
- Management elected to redeem \$3 million of remaining outstanding convertible debt
  - Redemption notices delivered May 18<sup>th</sup>
  - All holders have elected to convert debt into common stock
  - All conversions expected to be completed by year-end FY11
  - Will decrease quarterly interest expense and remove associated debt from the balance sheet
- Expect to enter FY12 with strong cash and no debt


# FY11 Outlook



- Raised annual revenue and operating income guidance in May
- Expect FY11 revenue in range of \$37 million \$39 million
- Expect FY11 operating income in range of \$2.5 million - \$3.0 million (operating profit margin of ~ 8%)
- Improved balance sheet
  - Strong cash & no debt at year-end FY11

FY11 Year-End: June 30, 2011

## Long-Term Growth Potential



Lifevantage.

# LifeVantage Corporation



